Phase 3 Recruiting Industry
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in Iowa: - University of Iowa ( Site 0074) — Iowa City, Iowa
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 2 Recruiting Academic/Other
This phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced colorectal cancer that has spread to up to 4 body sites (limited …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Iowa: - UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa
- Mercy Cancer Center-West Lakes — Clive, Iowa
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic — Clive, Iowa
- Greater Regional Medical Center — Creston, Iowa
Phase 2 Recruiting Network
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after the…
Sponsor: NSABP Foundation Inc
NCT ID: NCT07058012
Sites in Iowa: - University of Iowa - Holden Comprehensive Cancer Center — Iowa City, Iowa
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uv…
Sponsor: IDEAYA Biosciences
NCT ID: NCT03947385
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1 Recruiting Industry
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Sponsor: Kura Oncology, Inc.
NCT ID: NCT06026410
Sites in Iowa: - University of Iowa Hospitals & Clinics — Iowa City, Iowa
Phase 1 Recruiting Industry
ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic). Claudin 4 protein, or …
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT05719558
Sites in Iowa: - University of Iowa Hospitals — Iowa City, Iowa
Phase 1 Recruiting Industry
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to e…
Sponsor: Aktis Oncology, Inc.
NCT ID: NCT07020117
Sites in Iowa: - University of Iowa — Iowa City, Iowa
Phase 1 Recruiting Industry
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic …
Sponsor: Orano Med Theranostics, SAS
NCT ID: NCT05283330
Sites in Iowa: - University of Iowa Health Care — Iowa City, Iowa
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Iowa: - UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- University of Iowa Healthcare Cancer Services Quad Cities — Bettendorf, Iowa
- Physicians' Clinic of Iowa PC — Cedar Rapids, Iowa
- Oncology Associates at Mercy Medical Center — Cedar Rapids, Iowa
- Mercy Cancer Center-West Lakes — Clive, Iowa
NA Recruiting Academic/Other
This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Iowa: - Mary Greeley Medical Center — Ames, Iowa
- McFarland Clinic - Ames — Ames, Iowa
- UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- McFarland Clinic - Boone — Boone, Iowa
- Mercy Hospital — Cedar Rapids, Iowa
Recruiting Academic/Other
This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT03998202
Sites in Iowa: - UI Health Care Mission Cancer and Blood - Ankeny Clinic — Ankeny, Iowa
- Saint Anthony Regional Hospital — Carroll, Iowa
- Physicians' Clinic of Iowa PC — Cedar Rapids, Iowa
- Oncology Associates at Mercy Medical Center — Cedar Rapids, Iowa
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic — Clive, Iowa